Argenx reported successful Phase 3 clinical trial results for its drug VYVGART Hytrulo, targeting autoimmune myositis, especially benefiting patients with IMNM who lack approved therapies. The trial met its primary endpoint with statistically significant improvement, boosting investor confidence. Analyst Wedbush raised Argenx's price target to $1,150, indicating a potential 16.42% stock upside. This development highlights Argenx's progress in addressing severe autoimmune diseases and could drive future growth.
BDR Pharmaceuticals has filed a lawsuit against the FDA, disputing the agency's refusal to accept an abbreviated new drug application referencing Phathom Pharmaceuticals' VOQUEZNA. BDR claims the FDA wrongly extended Phathom's exclusivity period unde...
Ipsos achieved 2.0% organic revenue growth in Q3 2026, up from 0.8% in H1, driven by strong performances in EMEA, China, and citizen-related activities. The company updated its 2026 organic growth target to 1.2%-1.5%, reflecting improved momentum and...
Ipsos posted €636.2 million revenue in Q3 2026 with 2.0% organic growth, up from 0.8% in H1, led by strong performances in EMEA, China, and its Citizens business. The company updated its full-year organic growth outlook to 1.2%-1.5%, citing ongoing g...
Signify reported third-quarter 2026 results with sales of EUR 1,367 million, a slight decline in comparable sales by 3.4%, but improved adjusted EBITA of EUR 145 million and a margin increase to 10.6%. Net income rose to EUR 88 million and free cash ...
Huddled Group PLC's shares rose 14% after it agreed to acquire AEWW, its joint venture partner on the Whatnot live shopping platform. The deal involves issuing 38.7 million new shares valued at £290,000, subject to due diligence and approvals. Full o...
